Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Multiple Myeloma 55Recurrence 14Neoplasms, Plasma Cell 9Primary Myelofibrosis 3Polycythemia Vera 3Neoplasms 3Waldenstrom Macroglobulinemia 2Plasmacytoma 2Myeloproliferative Disorders 2Hematologic Diseases 2Thrombocytosis 1Thrombocythemia, Essential 1Smoldering Multiple Myeloma 1Sarcoma, Kaposi 1Sarcoma 1Pancreatic Neoplasms 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Leukemia, Plasma Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Megakaryoblastic, Acute 1Immunoglobulin Light-chain Amyloidosis 1Hodgkin Disease 1Glioma 1Ependymoma 1Central Nervous System Neoplasms 1

Interventions

Rituximab 155Cyclophosphamide 120fludarabine phosphate 71Whole-Body Irradiation 55Mycophenolic Acid 54Etoposide 53Peripheral Blood Stem Cell Transplantation 46fludarabine 45Melphalan 44Granulocyte Colony-Stimulating Factor 43Busulfan 43Tacrolimus 39Filgrastim 37Vincristine 33Cyclosporine 31Bendamustine Hydrochloride 31Prednisone 29Doxorubicin 29Antilymphocyte Serum 28Methotrexate 27Cytarabine 27Lenalidomide 23Carmustine 22Bortezomib 22plerixafor 20Dexamethasone 19Thiotepa 17Stem Cell Transplantation 17Radiotherapy 17tositumomab I-131 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, Non-Hodgkin × pomalidomide × Clear all
NCT01592370 2025-10-22

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Bristol-Myers Squibb

Phase 1/2 Completed
320 enrolled 35 charts
LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡